OPTN/SRTR 2021 Annual Data Report: Pancreas

Am J Transplant. 2023 Feb;23(2 Suppl 1):S121-S177. doi: 10.1016/j.ajt.2023.02.005.

Abstract

The number of pancreas transplants in the United States was largely unchanged in 2021 at 963 transplants compared with 962 in 2020, showing that recovery from the COVID-19 pandemic was not as pronounced in pancreas transplantation as in other organs. The number of simultaneous pancreas-kidney transplants (SPKs) decreased from 827 to 820, whereas the number of pancreas-after-kidney transplants and pancreas transplants alone increased marginally to compensate. The proportion of patients with type 2 diabetes on the waiting list increased to 22.9% in 2021, compared with 20.1% in 2020. Consequently, the proportion of transplants in patients with type 2 diabetes increased from 21.3% in 2020 to 25.9% in 2021. The proportion of transplants in older recipients (aged 55 years or older) also increased to 13.5% in 2021 from 11.7% in 2020. Outcomes after SPK continue to be the best of the three categories of pancreas transplants: 1-year graft failure for kidney at 5.7% and pancreas at 10.5% for transplants performed in 2020. The proportion of pancreas transplants performed by medium-volume centers (11-24 transplants per year) increased sharply to 48.3% in 2021 from 35.1% in 2020, with a corresponding decrease in transplants in large-volume centers (25 or more transplants per year) to 15.9% in 2021 from 25.7% in 2020.

Keywords: Pancreas transplant; transplant outcomes; waitlist outcomes.

MeSH terms

  • Aged
  • COVID-19* / epidemiology
  • Diabetes Mellitus, Type 2*
  • Graft Survival
  • Humans
  • Pancreas
  • Pancreas Transplantation*
  • Tissue and Organ Procurement*
  • United States / epidemiology